Biologics

India’s healthcare boom has triggered an environmental emergency that most citizens never see. Every day, over 700 tonnes of potentially lethal waste emerge from hospitals nationwide. Syringes, blood-soaked dressings, pharmaceutical residues, and pathological materials pile up relentlessly. Mishandled, they become biological time bombs threatening communities and ecosystems alike. Yet within this crisis lies a burgeoning […]

Americans with diabetes face a brutal choice: pay exorbitant insulin prices or ration life-saving medication and risk severe health complications. This isn’t hyperbole—patients regularly skip doses, stretch supplies dangerously thin, or simply go without because insulin costs have spiraled beyond affordability for millions. Biocon Biologics, a global biosimilars leader, has extended its partnership with US-based

Most cancer treatments attack tumours directly with chemicals or radiation—blunt instruments causing collateral damage throughout the body. Theriva Biologics takes a fundamentally different approach: engineering viruses that selectively invade cancer cells, replicate inside them, and trigger immune responses while breaking down the protective barriers tumours build around themselves. This innovative strategy targets some of medicine’s

India manufactures the chemical compounds that keep millions alive globally, yet most people never realize these active pharmaceutical ingredients come from Indian factories. APIs—the actual therapeutic substances in medications—represent the foundation of every pill, injection, and treatment that global healthcare systems depend upon daily. India’s API market reached approximately $13 billion in 2023, producing over

Foreign investors grab headlines when they pump billions into Indian markets or trigger panic by pulling capital out. Yet India’s pharmaceutical industry increasingly depends on quieter, steadier hands—domestic institutional investors who don’t flee at the first sign of global turbulence. These homegrown investment powerhouses—mutual funds, insurance companies, pension funds, and banks—have fundamentally reshaped who finances

India’s biologics manufacturers just discovered something remarkable: going green actually saves money while winning international contracts simultaneously. Companies like Biocon, Sun Pharma, and Dr. Reddy’s aren’t embracing sustainable biomanufacturing because of environmental activism—they’re doing it because European and North American buyers now demand demonstrable green credentials for procurement contracts. India exported over $7 billion worth

India’s pharmaceutical industry has just placed a massive bet on artificial intelligence, and there’s no turning back now. Companies like Biocon, Dr. Reddy’s, and Cipla aren’t just experimenting with AI anymore—they’re integrating machine learning algorithms directly into drug discovery pipelines, clinical trial designs, and manufacturing processes. This shift from experimental pilots to strategic platforms represents

Ten years ago, India’s bioeconomy barely registered at $10 billion—a modest figure reflecting limited biotechnology commercialization and fragmented industry support. Fast forward to 2024, and that figure has exploded to $165.7 billion, representing one of the fastest biotechnology sector expansions globally. Yet India isn’t stopping there. The government has set an audacious target: building a

India’s pharmaceutical industry has operated for decades under a cloud of regulatory uncertainty. Approval timelines were unpredictable, expert panel selections remained opaque, and companies often complained about inconsistent decisions that cost time and money. That era is ending. The Central Drugs Standard Control Organisation has unveiled India’s first comprehensive formal rules governing drug approval panels,

India’s pharmaceutical industry stands at a crossroads. For decades, the country has dominated global generic drug production, earning its reputation as the world’s pharmacy. Yet this comfortable position masks a critical vulnerability: the absence of a complete drug innovation ecosystem. While India supplies over 60% of global vaccines and churns out affordable medicines for millions,